These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19107385)

  • 1. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
    Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
    Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
    Berto P; Maggi S; Noale M; Lopatriello S
    Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
    Blouin J; Dragomir A; Moride Y; Ste-Marie LG; Fernandes JC; Perreault S
    Br J Clin Pharmacol; 2008 Jul; 66(1):117-27. PubMed ID: 18460036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN; Burge RT; Marshall DA; Lindsay R
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
    Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
    Osteoporos Int; 2008 May; 19(5):687-97. PubMed ID: 18008100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
    Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
    Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
    Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R
    Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
    Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
    Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
    Ström O; Jönsson B; Kanis JA
    Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R; Blackhouse G; Adachi J
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
    Pazianas M; Abrahamsen B; Wang Y; Russell RG
    Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
    Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
    Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
    Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.